3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
3
Pain, Intractable
2
Cancer Pain
2
Spinal Surgery
1
Pain Related to Cancer
1
Mucositis
1
Leukemia
1
Breast Neoplasms
1
Bone Marrow Failure Disorders
1
Anemia, Aplastic
1
Adenocarcinoma
1
Interventions
Oxaliplatin
10
Fluorouracil
7
Leucovorin
6
Gemcitabine
6
Docetaxel
6
Capecitabine
6
Paclitaxel
5
Cisplatin
5
zolbetuximab
4
Ramucirumab
3
Pemetrexed
3
Drug Therapy
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
regorafenib
2
pembrolizumab
2
Vinorelbine
2
Surgical Procedures, Operative
2
Radiotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Cyclophosphamide
2
Chemoradiotherapy
2
Bevacizumab
2
Afatinib
2
vandetanib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Adenocarcinoma
×
Methadone
×
Clear all
NCT05325164
2022-12-05
METHADOPT
Ottawa Hospital Research Institute
Phase 3
Withdrawn